Up a level |
Gafar, Fajri, Wasmann, Roeland E, McIlleron, Helen M, Aarnoutse, Rob E, Schaaf, H Simon, Marais, Ben J, Agarwal, Dipti, Antwi, Sampson, Bang, Nguyen D, Bekker, Adrie et al (show 55 more authors)
(2022)
Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis.
The European respiratory journal, 61 (3).
p. 2201596.
Denti, Paolo, Wasmann, Roeland E, van Rie, Annelies, Winckler, Jana, Bekker, Adrie, Rabie, Helena, Hesseling, Anneke C, van der Laan, Louvina E, Gonzalez-Martinez, Carmen, Zar, Heather J et al (show 4 more authors)
(2021)
Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.
CLINICAL INFECTIOUS DISEASES, 75 (1).
pp. 141-151.
Francis, Jose, Zvada, Simbarashe P, Denti, Paolo, Hatherill, Mark, Charalambous, Salome, Mungofa, Stanley, Dawson, Rodney, Dorman, Susan, Gupte, Nikhil, Wiesner, Lubbe et al (show 6 more authors)
(2019)
A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63 (4).
e01964-e01918.